Submitted for Publication: October 28, 2014; final revision received January 15, 2015; accepted January 23, 2015.
Published Online: March 19, 2015. doi:10.1001/jamaophthalmol.2015.0357.
Study concept and design: Yang, Weleber, Pennesi.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Yang, Weleber, Pennesi.
Statistical analysis: Yang.
Administrative, technical, or material support: Chiang, Weleber, Pennesi.
Study supervision: Weleber, Pennesi.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and Dr Weleber is a consultant to Novartis, Pfizer, and Wellstat; is a member of the scientific advisory board for Applied Genetic Technologies Corp; and serves on the scientific advisory board for the Foundation Fighting Blindness (the relationship has been reviewed and managed by Oregon Health and Science University). Dr Weleber also reports having received grants and personal fees from the Foundation Fighting Blindness and Applied Genetic Technologies Corp, and other support from Sanofi-Fovea, all outside the submitted work. In addition, Dr Weleber has a patent (US patent 8,657,446, Method and apparatus for visual field monitoring, also known as Visual Field Monitoring and Analysis, or VFMA, which has not been issued). Dr Pennesi is on the advisory board for Sucampo Pharmaceuticals and received travel support from Imagine Eyes. Dr Pennesi also reports having received personal fees from Sucampo Pharmaceuticals outside the submitted work. No other disclosures are reported.
Funding/Support: This work was supported by grants CD-NMT-0714-0648-OHSU (Dr Yang) and CD-CL-0808-0469-OHSU (Dr Pennesi) from the Foundation Fighting Blindness, grant 1K08 EY0231186-01 from the National Institutes of Health (Dr Pennesi), Research to Prevent Blindness (Dr Pennesi), core grant P30EY010572 and unrestricted grant C-CL-0711-0534-OHSU01 from the Foundation Fighting Blindness (Casey Eye Institute), and an unrestricted grant from Research to Prevent Blindness (Casey Eye Institute).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.